Although anti-TNF still represents the only FDA-approved class of biologic treatment for moderate to severe HS, new emergent treatments have been shown to be potentially effective therapies in the management of unresponsive HS forms [10,11,17]. The gene discussed is TNF; the disease is histiocytic sarcoma.